Rigel Pharmaceuticals (RIGL) Total Liabilities (2010 - 2026)

Rigel Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $104.7 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 33.48% year-over-year to $104.7 million in Q1 2026; TTM through Mar 2026 was $104.7 million, a 33.48% decrease from a year earlier, with the FY2025 full-year figure at $122.1 million, down 24.01% from the prior year.
• Total Liabilities eased to $104.7 million in Q1 2026 per RIGL's latest filing, from $122.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $160.7 million in Q4 2024 and bottomed at $104.7 million in Q1 2026.
• The 5-year median for Total Liabilities is $147.2 million (2023), against an average of $140.7 million.
• Across the five-year window, Total Liabilities sank 38.02% in 2022 and grew 27.29% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $147.9 million in 2022, then decreased by 1.37% to $145.9 million in 2023, then increased by 10.16% to $160.7 million in 2024, then decreased by 24.01% to $122.1 million in 2025, then decreased by 14.25% to $104.7 million in 2026.
• Per Business Quant, the three latest RIGL Total Liabilities figures stand at $104.7 million (Q1 2026), $122.1 million (Q4 2025), and $124.9 million (Q3 2025).